From YMB minutes ago......
"Today Allergan Paid $3.3 Billion for Heptares Phase 1b Drug (Only 28 patients), What is AVXL Worth?
Fiercebiotech article title .."Solo again, Allergan strikes a $3.3B deal on Heptares' Alzheimer's portfolio"
April 6, 2016 | By John Carroll
Just hours after Allergan backed away from a $160 billion merger with Pfizer, the company has bounced back with a $3.3 billion licensing deal for global rights to a portfolio of drugs for neurological disorders from the UK's Heptares.
Here is what I think. AVXL has Phase 2a data in Alzheimers patients.and is worth MORE than Heptares. Here is why. Heptares has Phase 1b results that they reported in Feb 2016. However, it is not data showing improvement in cognition, only in 28 Healthy (not Alzheimers patients) and no evidence clinical efficacy, just evidence of brain activity in health patients.. NO COGNITIVE DATA. See details from Heptares Feb 2016 press release below....
The Phase 1b precision medicine study involved 28 healthy elderly subjects who received different doses of
HTL9936 and was designed to test the effect of drug on measures of brain activity while simultaneously monitoring side effects.
In the study, HTL9936 exhibited robust and statistically significant changes in brain electrical activity measured using multiple electroencephalography (EEG) biomarkers relevant to cognition, including effects on the P300 evoked response potential (p=0.0052). These pro-cognitive effects were seen at low doses and low blood concentrations that were safe and well tolerated"""
